[go: up one dir, main page]

CN116199698A - Functionalized D-glucal compound and preparation method thereof - Google Patents

Functionalized D-glucal compound and preparation method thereof Download PDF

Info

Publication number
CN116199698A
CN116199698A CN202310246203.8A CN202310246203A CN116199698A CN 116199698 A CN116199698 A CN 116199698A CN 202310246203 A CN202310246203 A CN 202310246203A CN 116199698 A CN116199698 A CN 116199698A
Authority
CN
China
Prior art keywords
glucal
group
vii
acetone
functionalized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310246203.8A
Other languages
Chinese (zh)
Inventor
徐华栋
王小漫
沈美华
李亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou University
Original Assignee
Changzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changzhou University filed Critical Changzhou University
Priority to CN202310246203.8A priority Critical patent/CN116199698A/en
Publication of CN116199698A publication Critical patent/CN116199698A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention discloses a functionalized D-glucose compound and a preparation method thereof, wherein the functionalized D-glucose compound uses a key intermediate 4, 6-O-acetonylidene-D-glucose, and adopts different reaction technologies to install six different functional groups on a hydroxyl group at a 3-position of the functionalized D-glucose compound to obtain six corresponding functionalized glucose derivatives. The novel glycal has potential application value in the fields of synthetic chemistry and pharmaceutical chemistry.

Description

功能化D-葡萄烯糖化合物及其制备方法Functionalized D-glucal compound and preparation method thereof

技术领域Technical Field

本发明属于精细化工领域和糖化学领域,涉及手性含糖中间体的利用和转化,特别地公开了一种新型的功能化D-葡萄烯糖化合物及其制备方法。The invention belongs to the fields of fine chemical industry and sugar chemistry, relates to the utilization and conversion of chiral sugar-containing intermediates, and particularly discloses a novel functionalized D-glucal compound and a preparation method thereof.

背景技术Background Art

D-葡萄烯糖(I)是一种非常重要的糖类衍生物,可以方便地从葡萄糖或甘露糖制备而来。D-葡萄烯糖继承了天然糖D-葡萄糖的手性,其衍生物广泛地应用于有机合成中,是方便的六碳手性砌块。比较常用且重要的D-葡萄烯糖衍生物包括II、III、IV、V和VI中的任一种,具体如下:D-glucal (I) is a very important sugar derivative that can be easily prepared from glucose or mannose. D-glucal inherits the chirality of natural sugar D-glucose, and its derivatives are widely used in organic synthesis as convenient six-carbon chiral building blocks. The more commonly used and important D-glucal derivatives include any of II, III, IV, V and VI, as follows:

Figure BDA0004126033220000011
Figure BDA0004126033220000011

通过这些衍生物可以制备很多手性药物分子。比如以其三乙酰衍生物II为起始原料和手性源,可以制备Restricticin、SGLT-2inhibitor、Bergenin、Papulacandin D、Tricyclic flavonoid和Papulacandins A等。另外适当保护的烯糖还是方便的糖苷化给体;同时围绕着葡萄烯糖衍生物的环内烯醚官能团,许多有趣有用的反应被开发出来,大量结构新颖的手性化合物被制备出来。充分说明了D-葡萄烯糖及其衍生物在有机合成和药物化学等领域的重要性和高价值。Many chiral drug molecules can be prepared through these derivatives. For example, using its triacetyl derivative II as the starting material and chiral source, Restricticin, SGLT-2 inhibitor, Bergenin, Papulacandin D, Tricyclic flavonoid and Papulacandins A can be prepared. In addition, properly protected alkenyls are convenient glycosylation donors; at the same time, many interesting and useful reactions have been developed around the intracyclic alkenyl ether functional groups of glucal derivatives, and a large number of chiral compounds with novel structures have been prepared. This fully demonstrates the importance and high value of D-glucal and its derivatives in organic synthesis and medicinal chemistry.

Figure BDA0004126033220000021
Figure BDA0004126033220000021

发明内容Summary of the invention

本发明的目的在于提供一种新型的功能化D-葡萄烯糖化合物及其制备方法。在本发明中公开的功能化D-葡萄烯糖化合物制备方法的创新性在于在3-位羟基上安装了六种不同的官能基团,这些基团具有与烯糖环内烯醚反应,生成新结构衍生物。The purpose of the present invention is to provide a novel functionalized D-glucal compound and a preparation method thereof. The novelty of the preparation method of the functionalized D-glucal compound disclosed in the present invention is that six different functional groups are installed on the 3-hydroxyl group, and these groups have the ability to react with the enol ether in the glucal ring to generate new structural derivatives.

一种功能化D-葡萄烯糖化合物,具有通式结构VII,根据其功能取代基FG的种类分别用如下结构式VII-a、VII-b、VII-c、VII-d、VII-e和VII-f表示:A functionalized D-glucal compound has a general structure VII, and is represented by the following structural formulas VII-a, VII-b, VII-c, VII-d, VII-e and VII-f respectively according to the type of its functional substituent FG:

Figure BDA0004126033220000031
Figure BDA0004126033220000031

优选地,其中一种为3-O-丙烯酰基-4,6-O-丙酮叉-D-葡萄烯糖(VII-a),其结构通式为:Preferably, one of them is 3-O-acryloyl-4,6-O-acetone-D-glucal (VII-a), and its general structural formula is:

Figure BDA0004126033220000032
Figure BDA0004126033220000032

其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种。The R group is selected from any one of -H, alkyl, alkenyl, alkynyl and aryl.

优选地,其中一种为3-O-丙烯基酯-4,6-O-丙酮叉-D-葡萄烯糖(VII-b),其结构通式为:Preferably, one of them is 3-O-propenyl ester-4,6-O-acetone-D-glucal (VII-b), and its general structural formula is:

Figure BDA0004126033220000033
Figure BDA0004126033220000033

其中,R基选自烷基、苄基、烯丙基中的任一种。The R group is selected from any one of an alkyl group, a benzyl group, and an allyl group.

优选地,其中一种为3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c),其结构通式为:Preferably, one of them is 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c), and its general structural formula is:

Figure BDA0004126033220000041
Figure BDA0004126033220000041

其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种。The R group is selected from any one of -H, alkyl, alkenyl, alkynyl and aryl.

优选地,其中一种为3-O-吡啶基-4,6-O-丙酮叉-D-葡萄烯糖(VII-d),其结构通式为:Preferably, one of them is 3-O-pyridyl-4,6-O-acetone-D-glucal (VII-d), and its general structural formula is:

Figure BDA0004126033220000042
Figure BDA0004126033220000042

其中,R基选自-H、卤素、烷基、烯基、炔基、芳基中的任一种。Wherein, the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, and aryl.

优选地,其中一种为3-O-苄基-4,6-O-丙酮叉-D-葡萄烯糖(VII-e),其结构通式为:Preferably, one of them is 3-O-benzyl-4,6-O-acetone-D-glucal (VII-e), and its general structural formula is:

Figure BDA0004126033220000043
Figure BDA0004126033220000043

其中,R基选自-H、卤素、烷基、烯基、炔基、芳基、硝基、酯基、醛基中的任一种。Wherein, the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, aryl, nitro, ester and aldehyde.

优选地,其中一种为3-O-亚甲基三氮唑-4,6-O-丙酮叉-D-葡萄烯糖(VII-f),其结构通式为:Preferably, one of them is 3-O-methylenetriazole-4,6-O-acetone-D-glucal (VII-f), and its general structural formula is:

Figure BDA0004126033220000051
Figure BDA0004126033220000051

其中,R基选自烷基、烯基、芳基、磺酰基中的任一种。The R group is selected from any one of an alkyl group, an alkenyl group, an aryl group, and a sulfonyl group.

优选地,所述功能化D-葡萄烯糖化合物的制备方法,其特征在于,所述功能化D-葡萄烯糖化合物的制备路线为:Preferably, the method for preparing the functionalized D-glucal compound is characterized in that the preparation route of the functionalized D-glucal compound is:

Figure BDA0004126033220000052
Figure BDA0004126033220000052

其中,3-O-丙烯酰基-4,6-O-丙酮叉-D-葡萄烯糖(VII-a),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与取代烯丙基羧酸a缩合,羧酸a的结构式为

Figure BDA0004126033220000053
其中R基选自-H、烷基、烯基、炔基、芳基中的任一种;Among them, 3-O-acryloyl-4,6-O-acetone-D-glucal (VII-a) is prepared by condensing 4,6-O-acetone-D-glucal VI with substituted allyl carboxylic acid a, wherein the structural formula of carboxylic acid a is
Figure BDA0004126033220000053
Wherein the R group is selected from any one of -H, alkyl, alkenyl, alkynyl, and aryl;

3-O-丙烯基酯-4,6-O-丙酮叉-D-葡萄烯糖(VII-b),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与丙炔酯b加成,丙炔酯b结构式为

Figure BDA0004126033220000054
其中,R基选自烷基、苄基、烯丙基中的任一种。3-O-propenyl ester-4,6-O-acetone formate-D-glucal (VII-b), the preparation method of which is to use 4,6-O-acetone formate-D-glucal VI to add propargyl ester b, the structural formula of propargyl ester b is
Figure BDA0004126033220000054
The R group is selected from any one of an alkyl group, a benzyl group, and an allyl group.

优选地,所述的功能化D-葡萄烯糖化合物的制备方法,其特征在于,所述功能化D-葡萄烯糖化合物的制备路线为:Preferably, the method for preparing the functionalized D-glucal compound is characterized in that the preparation route of the functionalized D-glucal compound is:

Figure BDA0004126033220000061
Figure BDA0004126033220000061

其中,3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与丙炔卤代物c亲核取代,丙炔卤代物c结构式为

Figure BDA0004126033220000062
其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种,X选自Cl、Br、OMs中的任一种;Among them, 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c) is prepared by using 4,6-O-acetone-D-glucal VI and propyne halide c for nucleophilic substitution, and the structural formula of propyne halide c is
Figure BDA0004126033220000062
Wherein, the R group is selected from any one of -H, alkyl, alkenyl, alkynyl, and aryl, and X is selected from any one of Cl, Br, and OMs;

3-O-吡啶基-4,6-O-丙酮叉-D-葡萄烯糖(VII-d),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与吡啶卤代物d芳香亲核取代,吡啶卤代物d结构式为

Figure BDA0004126033220000063
其中R基选自-H、卤素、烷基、烯基、炔基、芳基中的任一种,X基选自F、Cl、Br、OMs中的任一种。3-O-pyridyl-4,6-O-acetone-D-glucal (VII-d), the preparation method of which is to use 4,6-O-acetone-D-glucal VI and pyridine halide d for aromatic nucleophilic substitution, the pyridine halide d has the structural formula
Figure BDA0004126033220000063
The R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, and aryl, and the X group is selected from any one of F, Cl, Br, and OMs.

优选地,所述的功能化D-葡萄烯糖化合物的制备方法,其特征在于,所述功能化D-葡萄烯糖化合物的制备路线为:Preferably, the method for preparing the functionalized D-glucal compound is characterized in that the preparation route of the functionalized D-glucal compound is:

Figure BDA0004126033220000071
Figure BDA0004126033220000071

其中,3-O-苄基-4,6-O-丙酮叉-D-葡萄烯糖(VII-e),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与苄基卤代物e亲核取代,苄基卤代物e结构式为

Figure BDA0004126033220000072
其中R基选自-H、卤素、烷基、烯基、炔基、芳基、硝基、酯基、醛基中的任一种,X基选自Cl、Br、OMs中的任一种;Among them, 3-O-benzyl-4,6-O-acetone-D-glucal (VII-e) is prepared by using 4,6-O-acetone-D-glucal VI and benzyl halide e for nucleophilic substitution, and the benzyl halide e has the structural formula
Figure BDA0004126033220000072
Wherein the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, aryl, nitro, ester, and aldehyde, and the X group is selected from any one of Cl, Br, and OMs;

3-O-亚甲基三氮唑-4,6-O-丙酮叉-D-葡萄烯糖(VII-f),其制备方法为使用3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c1)与叠氮化物f进行[3+2]环加成反应获得,叠氮化物f结构式为RN3,其中R基选自烷基、烯基、芳基、磺酰基中的任一种。3-O-methylenetriazole-4,6-O-acetone-D-glucal (VII-f), which is prepared by a [3+2] cycloaddition reaction of 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c 1 ) and azide f, wherein the structural formula of azide f is RN 3 , wherein the R group is selected from any one of an alkyl group, an alkenyl group, an aryl group, and a sulfonyl group.

本发明相对于现有技术的有益效果是:首次在4,6-O-丙酮叉-D-葡萄烯糖的3-O位安装了六种官能团,得到六类新的烯糖化合物。这些化合物不仅本身具有学术和潜在的药物化学价值,它们还可以方便地进一步转化为其它新物质,特别地可发生分子内的环化或重排反应等。The beneficial effects of the present invention over the prior art are: for the first time, six functional groups are installed at the 3-O position of 4,6-O-acetone-D-glucal to obtain six new glucal compounds. These compounds not only have academic and potential medicinal chemical value, but can also be conveniently further converted into other new substances, especially intramolecular cyclization or rearrangement reactions can occur.

具体实施方式DETAILED DESCRIPTION

一种功能化D-葡萄烯糖化合物,具有通式结构VII,根据其功能取代基FG的种类分别用如下结构式VII-a、VII-b、VII-c、VII-d、VII-e和VII-f表示:A functionalized D-glucal compound has a general structure VII, and is represented by the following structural formulas VII-a, VII-b, VII-c, VII-d, VII-e and VII-f respectively according to the type of its functional substituent FG:

Figure BDA0004126033220000081
Figure BDA0004126033220000081

本发明提供了所述功能化D-葡萄烯糖化合物的制备方法,具体制备路线为:The present invention provides a method for preparing the functionalized D-glucal compound, and the specific preparation route is:

Figure BDA0004126033220000091
Figure BDA0004126033220000091

具体地,这六种功能化D-葡萄烯糖化合物分别为:Specifically, the six functionalized D-glucal compounds are:

第一种,3-O-丙烯酰基-4,6-O-丙酮叉-D-葡萄烯糖VII-a的制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与取代烯丙基羧酸a缩合,羧酸a的结构式为

Figure BDA0004126033220000101
其中R基选自-H、烷基、烯基、炔基、芳基中的任一种;The first method is to prepare 3-O-acryloyl-4,6-O-acetone-D-glucal VII-a by condensing 4,6-O-acetone-D-glucal VI with substituted allyl carboxylic acid a, wherein the structural formula of carboxylic acid a is
Figure BDA0004126033220000101
Wherein the R group is selected from any one of -H, alkyl, alkenyl, alkynyl, and aryl;

第二种,3-O-丙烯基酯-4,6-O-丙酮叉-D-葡萄烯糖(VII-b),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与丙炔酯b加成,丙炔酯b结构式为

Figure BDA0004126033220000102
其中,R基选自烷基、苄基、烯丙基中的任一种;The second type, 3-O-propenyl ester-4,6-O-acetone foridene-D-glucal (VII-b), is prepared by adding 4,6-O-acetone foridene-D-glucal VI to propargyl ester b, the structural formula of which is
Figure BDA0004126033220000102
Wherein, the R group is selected from any one of an alkyl group, a benzyl group, and an allyl group;

第三种,3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与丙炔卤代物c亲核取代,丙炔卤代物c结构式为

Figure BDA0004126033220000103
其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种,X选自Cl、Br、OMs中的任一种。The third type, 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c), is prepared by using 4,6-O-acetone-D-glucal VI and propyne halide c for nucleophilic substitution. The structural formula of propyne halide c is
Figure BDA0004126033220000103
Wherein, the R group is selected from any one of -H, alkyl, alkenyl, alkynyl, and aryl, and X is selected from any one of Cl, Br, and OMs.

第四种,3-O-吡啶基-4,6-O-丙酮叉-D-葡萄烯糖(VII-d),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与吡啶卤代物d芳香亲核取代,吡啶卤代物d结构式为

Figure BDA0004126033220000104
其中R基选自-H、卤素、烷基、烯基、炔基、芳基中的任一种,X基选自F、Cl、Br、OMs中的任一种;The fourth type, 3-O-pyridyl-4,6-O-acetone-D-glucal (VII-d), is prepared by using 4,6-O-acetone-D-glucal VI to perform aromatic nucleophilic substitution with a pyridine halide d. The structural formula of the pyridine halide d is
Figure BDA0004126033220000104
Wherein the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, and aryl, and the X group is selected from any one of F, Cl, Br, and OMs;

第五种,3-O-苄基-4,6-O-丙酮叉-D-葡萄烯糖(VII-e),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与苄基卤代物e亲核取代,苄基卤代物e结构式为

Figure BDA0004126033220000105
其中R基选自-H、卤素、烷基、烯基、炔基、芳基、硝基、酯基、醛基中的任一种,X基选自Cl、Br、OMs中的任一种;The fifth type, 3-O-benzyl-4,6-O-acetone-D-glucal (VII-e), is prepared by using 4,6-O-acetone-D-glucal VI and benzyl halide e for nucleophilic substitution. The benzyl halide e has the structural formula
Figure BDA0004126033220000105
Wherein the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, aryl, nitro, ester, and aldehyde, and the X group is selected from any one of Cl, Br, and OMs;

第六种,3-O-亚甲基三氮唑-4,6-O-丙酮叉-D-葡萄烯糖(VII-f),其制备方法为使用3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c1)与叠氮化物f进行[3+2]环加成反应获得,叠氮化物f结构式为RN3,其中R基选自烷基、烯基、芳基、磺酰基中的任一种。The sixth type, 3-O-methylenetriazole-4,6-O-acetone-D-glucal (VII-f), is prepared by a [3+2] cycloaddition reaction of 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c 1 ) and azide f. The structural formula of azide f is RN 3 , wherein the R group is selected from any one of an alkyl group, an alkenyl group, an aryl group, and a sulfonyl group.

实施例1Example 1

Figure BDA0004126033220000111
Figure BDA0004126033220000111

将VI(540mg,3.01mmol)溶解在15mL无水二氯甲烷(DCM)中,在氮气氛围下向反应瓶中加入化合物a1(681.0mg,3.91mmol)4-二甲氨基吡啶(DMAP)(367.4mg,3.01mmol),然后将反应冷却至0℃,加入1,3-二环己基碳二亚胺(DCC)(806.69mg,3.91mmol),最后将反应逐渐升温至室温反应过夜。用TLC检测反应结束后,加水淬灭反应,然后用二氯甲烷(3x 10mL)萃取,然后用饱和食盐水15mL萃取,收集有机相用无水硫酸钠干燥,最后减压浓缩,快速通过柱层析得到VII-a1(566.5mg),白色固体,产率为55%。1H NMR(400MHz,CDCl3)δ7.54–7.40(m,3H),7.41–7.27(m,3H),6.88(d,J=8.7Hz,2H),6.37(dd,J=6.1,1.4Hz,1H),6.01(d,J=15.2Hz,1H),5.48(dt,J=7.8,1.7Hz,1H),4.81(dd,J=6.1,2.0Hz,1H),4.12(dd,J=9.8,7.9Hz,1H),3.98(t,J=4.5Hz,1H),3.92–3.79(m,2H),1.55(s,3H),1.43(s,3H).VI (540 mg, 3.01 mmol) was dissolved in 15 mL of anhydrous dichloromethane (DCM), and compound a 1 (681.0 mg, 3.91 mmol) and 4-dimethylaminopyridine (DMAP) (367.4 mg, 3.01 mmol) were added to the reaction bottle under a nitrogen atmosphere, and then the reaction was cooled to 0°C, 1,3-dicyclohexylcarbodiimide (DCC) (806.69 mg, 3.91 mmol) was added, and finally the reaction was gradually heated to room temperature and reacted overnight. After the reaction was detected by TLC, water was added to quench the reaction, and then extracted with dichloromethane (3x 10 mL), and then extracted with 15 mL of saturated brine, the organic phase was collected and dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure, and quickly passed through column chromatography to obtain VII-a 1 (566.5 mg) as a white solid with a yield of 55%. 1 H NMR (400MHz, CDCl 3 ) δ7.54–7.40(m,3H),7.41–7.27(m,3H),6.88(d,J=8.7Hz,2H),6.37(dd,J=6.1,1.4Hz,1H),6.01(d,J=15.2Hz,1H),5.48(dt,J=7.8,1 .7Hz,1H),4.81(dd,J=6.1,2.0Hz,1H),4.12(dd,J=9.8,7.9Hz,1H),3.98(t,J=4.5Hz,1H),3.92–3.79(m,2H),1.55(s,3H),1.43(s,3H).

实施例2Example 2

Figure BDA0004126033220000121
Figure BDA0004126033220000121

将VI(626.4mg,3.36mmol)溶解在15mL无水四氢呋喃中,然后在氮气保护下加入1,4-二氮杂二环[2.2.2]辛烷(DABCO),接着缓慢滴加b1,室温反应5h。反应结束后,混合物中加入20mL氢氧化钠水溶液(1M),乙醚(3x 15mL)萃取,收集有机相,用无水硫酸钠干燥,最后减压浓缩,通过硅胶柱纯化,最后得到VII-b1(660mg),白色固体,产率为79.9%。1H NMR(400MHz,CDCl3)δ7.60(d,J=12.4Hz,1H),6.39(dd,J=6.2,1.2Hz,1H),5.33(d,J=12.4Hz,1H),4.76(dd,J=6.2,1.9Hz,1H),4.60(dt,J=7.4,1.7Hz,1H),4.09–3.91(m,2H),3.89–3.74(m,2H),3.69(s,3H),1.51(s,3H),1.43(s,3H).VI (626.4 mg, 3.36 mmol) was dissolved in 15 mL of anhydrous tetrahydrofuran, and then 1,4-diazabicyclo[2.2.2]octane (DABCO) was added under nitrogen protection, followed by slow dropwise addition of b 1 , and the mixture was reacted at room temperature for 5 h. After the reaction, 20 mL of sodium hydroxide aqueous solution (1 M) was added to the mixture, and the mixture was extracted with ether (3 x 15 mL), the organic phase was collected, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure and purified by silica gel column to obtain VII-b 1 (660 mg) as a white solid with a yield of 79.9%. 1 H NMR (400MHz, CDCl 3 ) δ7.60 (d, J=12.4Hz, 1H), 6.39 (dd, J=6.2, 1.2Hz, 1H), 5.33 (d, J=12.4Hz, 1H), 4.76 (dd, J=6.2, 1.9Hz, 1H), 4.60 (dt, J=7.4, 1.7Hz, 1H) ,4.09–3.91(m,2H),3.89–3.74(m,2H),3.69(s,3H),1.51(s,3H),1.43(s,3H).

实施例3Example 3

Figure BDA0004126033220000122
Figure BDA0004126033220000122

将VI(500mg,2.69mmol)溶解在10mL无水四氢呋喃中,然后将反应瓶冷却至0℃,在氮气保护下加入氢化钠(161.1mg,4.03mmol,60%),将混合物在0℃反应30分钟,随后将c1(0.28mL,3.22mmol)缓慢加入反应体系中,室温反应2h。反应结束后,向体系中加入冰水淬灭反应,然后用乙酸乙酯(3x 15mL)萃取,收集有机相,用饱和食盐水(20mL)干燥,然后有机相用无水硫酸钠干燥,最后减压浓缩,快速通过硅胶柱纯化产物,最后得到VII-c1(306mg),无色液体,产率为50%。1H NMR(400MHz,CDCl3)δ6.30(d,J=6.2Hz,1H),4.87–4.65(m,1H),4.42–4.16(m,3H),4.03–3.86(m,2H),3.81(t,J=10.5Hz,1H),3.71(td,J=10.3,5.6Hz,1H),2.43(s,1H),1.51(s,3H),1.40(s,3H).VI (500 mg, 2.69 mmol) was dissolved in 10 mL of anhydrous tetrahydrofuran, and then the reaction flask was cooled to 0°C. Sodium hydride (161.1 mg, 4.03 mmol, 60%) was added under nitrogen protection, and the mixture was reacted at 0°C for 30 minutes, and then c 1 (0.28 mL, 3.22 mmol) was slowly added to the reaction system, and the reaction was carried out at room temperature for 2 hours. After the reaction was completed, ice water was added to the system to quench the reaction, and then ethyl acetate (3 x 15 mL) was used for extraction, and the organic phase was collected and dried with saturated brine (20 mL), and then the organic phase was dried with anhydrous sodium sulfate, and finally concentrated under reduced pressure, and the product was quickly purified by silica gel column to obtain VII-c 1 (306 mg), a colorless liquid, with a yield of 50%. 1 H NMR (400MHz, CDCl 3 ) δ6.30(d,J=6.2Hz,1H),4.87–4.65(m,1H),4.42–4.16(m,3H),4.03–3.86(m,2H),3.81(t,J=10.5Hz,1H),3.71(td,J=10.3,5.6Hz, 1H),2.43(s,1H),1.51(s,3H),1.40(s,3H).

实施例4Example 4

Figure BDA0004126033220000131
Figure BDA0004126033220000131

将VI(300mg,1.61mmol)溶解在20mL无水四氢呋喃中,抽空换氮三次,然后冷却至0℃,氮气保护下加入氢化钠(161.1mg,4.03mmol,60%),然后0℃下搅拌30分钟,接着向混合物中加入d1,室温反应2小时。反应结束后,向混合物中加入20mL水淬灭反应,然后用然后用乙酸乙酯(3x 15mL)萃取水相,收集有机相,用饱和食盐水(20mL)洗涤,然后有机相用无水硫酸钠干燥,最后减压浓缩,快速通过硅胶柱纯化产物,最后得到化合物VII-d1(376.7mg),无色液体,产率为75.8%。1H NMR(400MHz,CDCl3)δ9.16–8.99(m,1H),8.36(dd,J=9.1,2.8Hz,1H),7.04–6.63(m,1H),6.40(dd,J=6.1,1.4Hz,1H),5.91–5.64(m,1H),4.89(dd,J=6.1,2.0Hz,1H),4.30–4.17(m,1H),3.95(ddd,J=8.4,6.6,3.5Hz,3H),1.57(s,3H),1.41(s,3H).VI (300 mg, 1.61 mmol) was dissolved in 20 mL of anhydrous tetrahydrofuran, evacuated and replaced with nitrogen three times, then cooled to 0°C, sodium hydride (161.1 mg, 4.03 mmol, 60%) was added under nitrogen protection, and then stirred at 0°C for 30 minutes, and then d 1 was added to the mixture, and reacted at room temperature for 2 hours. After the reaction was completed, 20 mL of water was added to the mixture to quench the reaction, and then the aqueous phase was extracted with ethyl acetate (3x 15 mL), the organic phase was collected, washed with saturated brine (20 mL), and then the organic phase was dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure, and the product was quickly purified by silica gel column to obtain compound VII-d 1 (376.7 mg), a colorless liquid, with a yield of 75.8%. 1 H NMR (400MHz, CDCl 3 ) δ9.16–8.99(m,1H),8.36(dd,J=9.1,2.8Hz,1H),7.04–6.63(m,1H),6.40(dd,J=6.1,1.4Hz,1H),5.91–5.64(m,1H),4.89(dd,J=6.1 ,2.0Hz,1H),4.30–4.17(m,1H),3.95(ddd,J=8.4,6.6,3.5Hz,3H),1.57(s,3H),1.41(s,3H).

实施例5Example 5

Figure BDA0004126033220000141
Figure BDA0004126033220000141

将VI(200mg,1.07mmol)溶解在15mL无水四氢呋喃中,抽空换氮三次,然后冷却至0℃,氮气保护下加入氢化钠(85.92mg,2.15mmol,60%),然后0℃下搅拌30分钟,接着向混合物中加入e1,室温反应2小时。反应结束后,向混合物中加入20mL水淬灭反应,然后用然后用乙酸乙酯(3x 15mL)萃取水相,收集有机相,用饱和食盐水(20mL)洗涤,然后有机相用无水硫酸钠干燥,最后减压浓缩,快速通过硅胶柱纯化产物,最后得到化合物VII-e1(233mg),无色液体,产率为61%。1H NMR(400MHz,CDCl3)δ7.53(ddd,J=4.9,3.1,1.0Hz,2H),7.31(td,J=7.5,1.1Hz,1H),7.15(dd,J=7.7,1.6Hz,1H),6.34(dd,J=6.1,1.6Hz,1H),4.88–4.78(m,2H),4.75–4.68(m,1H),4.25(dt,J=7.3,1.8Hz,1H),4.05(dd,J=10.3,7.3Hz,1H),3.96(dd,J=10.8,5.6Hz,1H),3.85(t,J=10.5Hz,1H),3.76(dd,J=10.3,5.6Hz,1H),1.49(s,3H),1.44(s,3H).VI (200 mg, 1.07 mmol) was dissolved in 15 mL of anhydrous tetrahydrofuran, evacuated and replaced with nitrogen three times, then cooled to 0°C, sodium hydride (85.92 mg, 2.15 mmol, 60%) was added under nitrogen protection, and then stirred at 0°C for 30 minutes, and then e 1 was added to the mixture, and reacted at room temperature for 2 hours. After the reaction was completed, 20 mL of water was added to the mixture to quench the reaction, and then the aqueous phase was extracted with ethyl acetate (3x 15 mL), the organic phase was collected, washed with saturated brine (20 mL), and then the organic phase was dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure, and the product was quickly purified by silica gel column to obtain compound VII-e 1 (233 mg), a colorless liquid with a yield of 61%. 1 H NMR (400 MHz, CDCl 3 )δ7.53(ddd,J=4.9,3.1,1.0Hz,2H),7.31(td,J=7.5,1.1Hz,1H),7.15(dd,J=7.7,1.6Hz,1H),6.34(dd,J=6.1,1.6Hz,1H),4.88–4.78(m,2H),4.75–4.68( m,1H),4.2 5(dt,J=7.3,1.8Hz,1H),4.05(dd,J=10.3,7.3Hz,1H),3.96(dd,J=10.8,5.6Hz,1H),3.85(t,J=10.5Hz,1H),3.76(dd,J=10.3,5.6Hz,1H),1.49(s,3H),1.4 4(s,3H).

实施例6Example 6

Figure BDA0004126033220000142
Figure BDA0004126033220000142

将TcCu(51.47mg,0.27mmol)溶解在5mL无水甲苯中,然后进行氮气保护,接着将化合物VII-c1(500mg,2.69mmol)溶解在15mL甲苯溶液中,将f1(582.5mg,2.95mmol)溶解在15mL甲苯溶液中,依次将二者加入到噻吩-2-甲酸亚铜(TcCu)中,室温反应。反应结束后,向反应体系中加入20mL水,用乙酸乙酯(3x 20mL)萃取,收集有机相,用饱和食盐水(20mL)干燥,然后有机相用无水硫酸钠干燥,最后减压浓缩,快速通过硅胶柱纯化产物VII-f1(802.3mg),产率为71%。1H NMR(400MHz,CDCl3)δ8.16(s,1H),8.16(s,1H),7.99(d,J=8.4Hz,2H),7.38(d,J=8.1Hz,2H),6.33(dd,J=6.1,1.4Hz,1H),4.98–4.64(m,3H),4.32–4.12(m,1H),4.06–3.63(m,5H),2.45(s,3H),2.17(s,1H),1.48(d,J=13.9Hz,3H),1.45(d,J=6.3Hz,3H).TcCu (51.47 mg, 0.27 mmol) was dissolved in 5 mL of anhydrous toluene, and then nitrogen protection was performed. Then, compound VII-c 1 (500 mg, 2.69 mmol) was dissolved in 15 mL of toluene solution, and compound f 1 (582.5 mg, 2.95 mmol) was dissolved in 15 mL of toluene solution, and the two were added to thiophene-2-carboxylic acid cuprous acid (TcCu) in sequence, and reacted at room temperature. After the reaction was completed, 20 mL of water was added to the reaction system, and extracted with ethyl acetate (3 x 20 mL), and the organic phase was collected and dried with saturated brine (20 mL), and then the organic phase was dried with anhydrous sodium sulfate, and finally concentrated under reduced pressure, and the product VII-f 1 (802.3 mg) was quickly purified by silica gel column, and the yield was 71%. 1 H NMR (400MHz, CDCl 3 ) δ8.16(s,1H),8.16(s,1H),7.99(d,J=8.4Hz,2H),7.38(d,J=8.1Hz,2H),6.33(dd,J=6.1,1.4Hz,1H),4.98–4.64(m,3H),4.32–4.1 2(m,1H),4.06–3.63(m,5H),2.45(s,3H),2.17(s,1H),1.48(d,J=13.9Hz,3H),1.45(d,J=6.3Hz,3H).

本发明公开了若干种新型葡萄烯糖分子及其制备方法。具体公开了六种3-位羟基上官能化的葡萄烯糖化合物及其合成方法,该类化合物使用关键中间体4,6-O-丙酮叉-D-葡萄烯糖,采用不同的反应技术,在其3-位的羟基上安装六种不同的官能团,得到相应的功能化的六种葡萄烯糖衍生物。这些新型烯糖在合成化学合药物化学领域具有潜在的应用价值。The present invention discloses several novel glucal molecules and preparation methods thereof. Specifically, six glucal compounds functionalized on the 3-hydroxyl group and synthesis methods thereof are disclosed. The compounds use the key intermediate 4,6-O-acetone-D-glucal and adopt different reaction technologies to install six different functional groups on the 3-hydroxyl group thereof to obtain six functionalized glucal derivatives. These novel glucal molecules have potential application value in the fields of synthetic chemistry and medicinal chemistry.

以上述依据本发明的较佳实施例为启示,通过上述的说明内容,相关工作人员完全可以在不偏离本项发明技术思想的范围内,进行多样的变更以及修改。本项发明的技术性范围并不局限于说明书上的内容,必须要根据权利要求范围来确定其技术性范围。Based on the above preferred embodiments of the present invention, the relevant staff can make various changes and modifications without departing from the technical concept of the present invention through the above description. The technical scope of the present invention is not limited to the content in the specification, and its technical scope must be determined according to the scope of the claims.

Claims (10)

1.一种功能化D-葡萄烯糖化合物,其特征在于,该功能化D-葡萄烯糖化合物具有通式结构VII,根据其功能取代基FG的种类分别用如下结构式VII-a、VII-b、VII-c、VII-d、VII-e和VII-f表示:
Figure FDA0004126033210000011
1. A functionalized D-glucal compound, characterized in that the functionalized D-glucal compound has a general structure VII, and is represented by the following structural formulas VII-a, VII-b, VII-c, VII-d, VII-e and VII-f respectively according to the type of its functional substituent FG:
Figure FDA0004126033210000011
2.根据权利要求1所述的功能化D-葡萄烯糖化合物,其特征在于,其中一种为3-O-丙烯酰基-4,6-O-丙酮叉-D-葡萄烯糖(VII-a),其结构通式为:2. The functionalized D-glucal compound according to claim 1, wherein one of the compounds is 3-O-acryloyl-4,6-O-acetone-D-glucal (VII-a), and the general structural formula thereof is:
Figure FDA0004126033210000012
Figure FDA0004126033210000012
其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种。The R group is selected from any one of -H, alkyl, alkenyl, alkynyl and aryl.
3.根据权利要求1所述的功能化D-葡萄烯糖化合物,其特征在于,其中一种为3-O-丙烯基酯-4,6-O-丙酮叉-D-葡萄烯糖(VII-b),其结构通式为:3. The functionalized D-glucal compound according to claim 1, wherein one of the compounds is 3-O-propenyl ester-4,6-O-acetone idene-D-glucal (VII-b), and the general structural formula thereof is:
Figure FDA0004126033210000021
Figure FDA0004126033210000021
其中,R基选自烷基、苄基、烯丙基中的任一种。The R group is selected from any one of an alkyl group, a benzyl group, and an allyl group.
4.根据权利要求1所述的功能化D-葡萄烯糖化合物,其特征在于,其中一种为3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c),其结构通式为:4. The functionalized D-glucal compound according to claim 1, wherein one of the compounds is 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c), and the general structural formula thereof is:
Figure FDA0004126033210000022
Figure FDA0004126033210000022
其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种。The R group is selected from any one of -H, alkyl, alkenyl, alkynyl and aryl.
5.根据权利要求1所述的功能化D-葡萄烯糖化合物,其特征在于,其中一种为3-O-吡啶基-4,6-O-丙酮叉-D-葡萄烯糖(VII-d),其结构通式为:5. The functionalized D-glucal compound according to claim 1, wherein one of the compounds is 3-O-pyridyl-4,6-O-acetone-D-glucal (VII-d), and the general structural formula thereof is:
Figure FDA0004126033210000023
Figure FDA0004126033210000023
其中,R基选自-H、卤素、烷基、烯基、炔基、芳基中的任一种。Wherein, the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, and aryl.
6.根据权利要求1所述的功能化D-葡萄烯糖化合物,其特征在于,其中一种为3-O-苄基-4,6-O-丙酮叉-D-葡萄烯糖(VII-e),其结构通式为:6. The functionalized D-glucal compound according to claim 1, wherein one of the compounds is 3-O-benzyl-4,6-O-acetone-D-glucal (VII-e), and the general structural formula thereof is:
Figure FDA0004126033210000031
Figure FDA0004126033210000031
其中,R基选自-H、卤素、烷基、烯基、炔基、芳基、硝基、酯基、醛基中的任一种。Wherein, the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, aryl, nitro, ester and aldehyde.
7.根据权利要求1所述的功能化D-葡萄烯糖化合物,其特征在于,其中一种为3-O-亚甲基三氮唑-4,6-O-丙酮叉-D-葡萄烯糖(VII-f),其结构通式为:7. The functionalized D-glucal compound according to claim 1, wherein one of the compounds is 3-O-methylenetriazole-4,6-O-acetone-D-glucal (VII-f), and the general structural formula thereof is:
Figure FDA0004126033210000032
Figure FDA0004126033210000032
其中,R基选自烷基、烯基、芳基、磺酰基中的任一种。The R group is selected from any one of an alkyl group, an alkenyl group, an aryl group, and a sulfonyl group.
8.根据权利要求1所述的功能化D-葡萄烯糖化合物的制备方法,其特征在于,所述功能化D-葡萄烯糖化合物的制备路线为:8. The method for preparing a functionalized D-glucal compound according to claim 1, characterized in that the preparation route of the functionalized D-glucal compound is:
Figure FDA0004126033210000033
Figure FDA0004126033210000033
其中,3-O-丙烯酰基-4,6-O-丙酮叉-D-葡萄烯糖(VII-a),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与取代烯丙基羧酸a缩合,羧酸a的结构式为
Figure FDA0004126033210000034
其中R基选自-H、烷基、烯基、炔基、芳基中的任一种;
Among them, 3-O-acryloyl-4,6-O-acetone-D-glucal (VII-a) is prepared by condensing 4,6-O-acetone-D-glucal VI with substituted allyl carboxylic acid a, wherein the structural formula of carboxylic acid a is
Figure FDA0004126033210000034
Wherein the R group is selected from any one of -H, alkyl, alkenyl, alkynyl, and aryl;
3-O-丙烯基酯-4,6-O-丙酮叉-D-葡萄烯糖(VII-b),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与丙炔酯b加成,丙炔酯b结构式为
Figure FDA0004126033210000041
其中,R基选自烷基、苄基、烯丙基中的任一种。
3-O-propenyl ester-4,6-O-acetone formate-D-glucal (VII-b), the preparation method of which is to use 4,6-O-acetone formate-D-glucal VI to add propargyl ester b, the structural formula of propargyl ester b is
Figure FDA0004126033210000041
The R group is selected from any one of an alkyl group, a benzyl group, and an allyl group.
9.根据权利要求1所述的功能化D-葡萄烯糖化合物的制备方法,其特征在于,所述功能化D-葡萄烯糖化合物的制备路线为:9. The method for preparing a functionalized D-glucal compound according to claim 1, wherein the preparation route of the functionalized D-glucal compound is:
Figure FDA0004126033210000042
Figure FDA0004126033210000042
其中,3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与丙炔卤代物c亲核取代,丙炔卤代物c结构式为
Figure FDA0004126033210000043
其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种,X选自Cl、Br、OMs中的任一种;
Among them, 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c) is prepared by using 4,6-O-acetone-D-glucal VI and propyne halide c for nucleophilic substitution, and the structural formula of propyne halide c is
Figure FDA0004126033210000043
Wherein, the R group is selected from any one of -H, alkyl, alkenyl, alkynyl, and aryl, and X is selected from any one of Cl, Br, and OMs;
3-O-吡啶基-4,6-O-丙酮叉-D-葡萄烯糖(VII-d),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与吡啶卤代物d芳香亲核取代,吡啶卤代物d结构式为
Figure FDA0004126033210000044
其中R基选自-H、卤素、烷基、烯基、炔基、芳基中的任一种,X基选自F、Cl、Br、OMs中的任一种。
3-O-pyridyl-4,6-O-acetone-D-glucal (VII-d), the preparation method of which is to use 4,6-O-acetone-D-glucal VI and pyridine halide d for aromatic nucleophilic substitution, the pyridine halide d has the structural formula
Figure FDA0004126033210000044
The R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, and aryl, and the X group is selected from any one of F, Cl, Br, and OMs.
10.根据权利要求1所述的功能化D-葡萄烯糖化合物的制备方法,其特征在于,所述功能化D-葡萄烯糖化合物的制备路线为:10. The method for preparing a functionalized D-glucal compound according to claim 1, characterized in that the preparation route of the functionalized D-glucal compound is:
Figure FDA0004126033210000051
Figure FDA0004126033210000051
其中,3-O-苄基-4,6-O-丙酮叉-D-葡萄烯糖(VII-e),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与苄基卤代物e亲核取代,苄基卤代物e结构式为
Figure FDA0004126033210000052
其中R基选自-H、卤素、烷基、烯基、炔基、芳基、硝基、酯基、醛基中的任一种,X基选自Cl、Br、OMs中的任一种;
Among them, 3-O-benzyl-4,6-O-acetone-D-glucal (VII-e) is prepared by using 4,6-O-acetone-D-glucal VI and benzyl halide e for nucleophilic substitution, and the benzyl halide e has the structural formula
Figure FDA0004126033210000052
Wherein the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, aryl, nitro, ester, and aldehyde, and the X group is selected from any one of Cl, Br, and OMs;
3-O-亚甲基三氮唑-4,6-O-丙酮叉-D-葡萄烯糖(VII-f),其制备方法为使用3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c1)与叠氮化物f进行[3+2]环加成反应获得,叠氮化物f结构式为RN3,其中R基选自烷基、烯基、芳基、磺酰基中的任一种。3-O-methylenetriazole-4,6-O-acetone-D-glucal (VII-f), which is prepared by a [3+2] cycloaddition reaction of 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c 1 ) and azide f, wherein the structural formula of azide f is RN 3 , wherein the R group is selected from any one of an alkyl group, an alkenyl group, an aryl group, and a sulfonyl group.
CN202310246203.8A 2023-03-15 2023-03-15 Functionalized D-glucal compound and preparation method thereof Pending CN116199698A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310246203.8A CN116199698A (en) 2023-03-15 2023-03-15 Functionalized D-glucal compound and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310246203.8A CN116199698A (en) 2023-03-15 2023-03-15 Functionalized D-glucal compound and preparation method thereof

Publications (1)

Publication Number Publication Date
CN116199698A true CN116199698A (en) 2023-06-02

Family

ID=86514637

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310246203.8A Pending CN116199698A (en) 2023-03-15 2023-03-15 Functionalized D-glucal compound and preparation method thereof

Country Status (1)

Country Link
CN (1) CN116199698A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101245057A (en) * 2007-02-13 2008-08-20 中国科学院成都生物研究所 A kind of preparation method of glucal
CN102397270A (en) * 2010-09-17 2012-04-04 苏州天人合生物技术有限公司 Application of glucal and glucal derivative in preparation of medicines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101245057A (en) * 2007-02-13 2008-08-20 中国科学院成都生物研究所 A kind of preparation method of glucal
CN102397270A (en) * 2010-09-17 2012-04-04 苏州天人合生物技术有限公司 Application of glucal and glucal derivative in preparation of medicines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACS: "RN:158053-94-2化合物", 《STN REGISTRY数据库》, 30 September 1994 (1994-09-30), pages 158053 - 94 *
ACS: "RN:58871-07-1化合物", 《STN REGISTRY数据库》, 16 November 1984 (1984-11-16), pages 58871 - 07 *
JOSE MARCO-CONTELLES: "Asymmetric Pauson-Khand Reaction. Cobalt-Mediated Cycloisomerization of 1, 6-Enynes in Carbohydrate Templates: Synthesis of Bis-Heteroannulated Pyranosides", 《J.ORG.CHEM.》, vol. 61, 31 December 1996 (1996-12-31), pages 7667 *
MARKUS LEIBELING等: "Domino access to highly substituted chromans and isochromans from carbohydrates", 《NATURE CHEMICAL BIOLOGY》, vol. 6, 24 January 2010 (2010-01-24), pages 22 *
PETER H. SEEBERGER等: "Selective formation of C-2 azidodeoxy-D-glucose derivatives from D-glucal precursors using the azidonitration reaction", 《CARBOHYDRATE RESEARCH》, vol. 328, 31 December 2000 (2000-12-31), pages 63 *

Similar Documents

Publication Publication Date Title
CN110330500B (en) Stereoselective synthesis method of 6 beta-hydroxy-7, 8-dihydro-morphine derivative
CN111233795A (en) Preparation method and application of chiral gamma-butyrolactone compound and derivative thereof
CN108558692B (en) A kind of preparation method of amide compound
CN106496183A (en) Macrolide derivatives of caffeic acid ester connection and preparation method thereof
CN114163436A (en) Diarylmethane derivative containing indolizine and preparation method and application thereof
CN114539252A (en) 2, 3-dihydroquinoline-4-ketone bioactive skeleton and synthesis method and application thereof
CN105348341B (en) A kind of method for preparing rope Citropten
CN116199698A (en) Functionalized D-glucal compound and preparation method thereof
CN103319497B (en) Preparation method of natural product Hirtellanine B and its derivatives and application in preparation of drugs for treating tumors
CN112979529A (en) Aromatic amine indole naphthoquinone derivative and preparation method thereof
CN110343117B (en) Process for the preparation of artemisinin derivatives
CN118598812A (en) Synthesis method of key intermediate of huperzine A
CN111187279A (en) Blue calyxine-biotin-based small molecule probe and its preparation method and application
CN115353522A (en) Regioselective synthesis and anti-tumor application of icaritin-norcantharidin conjugate
Kumar et al. A Novel One-pot Synthesis of 2 H-4-Chlorochromenes via the Vilsmeier Reaction of 2′-Hydroxychalcones
CN103848874B (en) The method of the tetra-acetylated-L-gulose of synthesis 1,3,4,6-
CN108329300B (en) Nitrobenzo [ d ] aza-quinazoline compound and preparation method and application thereof
CN115536571A (en) Preparation method of indole derivative
CN114605421A (en) Spiro-2, 3-dihydroquinoline-4-ketone-3, 4-dihydrocoumarin bioactive skeleton and synthesis method and application thereof
CN114891005B (en) Preparation process of Wupalision p-toluenesulfonate
CN114805168B (en) Pyrrolinones and synthesis method thereof
CN116283761B (en) A 3-alkenyl ketone substituted quinoline-2-one and a green synthesis method thereof
CN119060059B (en) Preparation process of Li Texi tenib tosylate
CN115925702B (en) A purification method of imidazo[4,5-C]pyridine derivatives and imidazo[4,5-C]pyridine derivatives
CN113292573B (en) Indolizine chromogen ketone compound with anti-tumor activity and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination